Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

6.570 +0.040 (+0.61%)
Streaming Delayed Price Updated: 10:22 AM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Get insights into the top gainers and losers of Thursday's after-hours session.
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Breaking Down Ardelyx: 4 Analysts Share Their Views
 
Via Benzinga
Earnings Scheduled For February 20, 2025
 
Via Benzinga
What Analysts Are Saying About Ardelyx Stock
 
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss Ardelyx Stock
 
Via Benzinga
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Beats Q3 Sales Estimates, Shares Climb
Ardelyx reported its third-quarter results after Thursday's closing bell. Here's a look at the details from the report: 
Via Benzinga
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
Award established to recognize leaders in the field of chronic kidney disease advocacy 
From Ardelyx, Inc.
Via GlobeNewswire
Tenapanor Approved in China for Hyperphosphatemia
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate in Upcoming Investor Conferences
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism
Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah. 
Via Stocktwits
Ardelyx Tops Estimates as Sales Surge
The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah. 
Via The Motley Fool
Palantir Rally Loses Steam, Walmart Outlook Disappoints: What's Driving Markets Thursday?
Stocks tumbled Thursday, with all major indices in the red, one day after the S&P 500 notched another all-time high in Wednesday’s trading session. 
Via Benzinga
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
Conference call scheduled for 8:00 a.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients’ health at risk 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.